Forecast

The analysts' average price target is +34,33€ (+72,17%). The median is +34,33€ (+72,17%).

Buy	8
Hold	1
Sell	2

News Go to news feed

Tactile Systems Technology reports 12% revenue growth to $329.5M for 2025

Tactile Systems Technology posted 2025 revenue of $329.5 million, up 12%, and ended the year with $83.4 million in cash. The company acquired Lymphotec and plans to integrate its fluid-monitoring technology to enhance patient surveillance and commercial workflows. Investments in a new CRM and expanded sales headcount are driving productivity gains, while updated Medicare coverage criteria have improved access to the FlexiTouch system. For 2026 the company issued guidance of 8%–11% revenue growth but warned a new Medicare prior authorization requirement for pneumatic compression devices could create a short-term headwind. » More on finance.yahoo.com
Tactile Systems misses EPS forecast in Q2 2025 but beats revenue expectations

Tactile Systems Technology missed earnings expectations in the second quarter of 2025, reporting EPS of $0.14, while revenue came in above forecasts at $78.9 million. The respiratory product segment saw particularly strong growth, but the missed EPS and a decline in adjusted EBITDA led to a slight drop in the share price. The company remains optimistic for the full year and expects revenue growth of 6-8%. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Tactile Systems Technology Inc has already paid 0,99€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Tactile Systems Technology Inc had revenue of 75.09m€ and net profit of 6.82m€

(EUR)	Jun 2026	YoY
Revenue	+75.09m	12,17%
Gross profit	+51.57m	3,39%
Net profit	+6.82m	149,92%
EBITDA	+8.06m	44,08%

Fundamentals

Metric	Value
Market capitalization	+452.20m€
Number of shares	22.56m
52-week high/low	+32,41€ - +10,99€
Dividends	No
Beta	0,82
P/E ratio	+21,43
PEG ratio	+0,28
P/B ratio	+2,37
P/S ratio	+1,50

Company profile

Tactile Systems Technology, Inc. ist ein Medizintechnikunternehmen, das sich mit der Entwicklung und Bereitstellung von medizinischen Geräten für chronische Krankheiten in den Vereinigten Staaten beschäftigt. Das Unternehmen bietet das Flexitouch Plus System an, ein pneumatisches Kompressionsgerät für die Behandlung von Lymphödemen; das Entre System, ein tragbares pneumatisches Kompressionsgerät, das für die Behandlung von Venenerkrankungen wie Lymphödemen und chronischer Veneninsuffizienz, einschließlich venöser Beingeschwüre, zu Hause verwendet wird; und AffloVest, einen tragbaren Hochfrequenz-Brustwand-Oszillationstest für die Behandlung von zurückgehaltenen Lungensekreten wie Bronchiektasien, zystischer Fibrose und verschiedenen neuromuskulären Erkrankungen. Das Unternehmen wurde 1995 gegründet und hat seinen Hauptsitz in Minneapolis, Minnesota.

Name	Tactile Systems Technology Inc
CEO	Sheri Louise Dodd
Headquarters	Minneapolis, mn USA
Website	tactilemedical.com
Sector	Consumer Discretionary
Industry	Household Durables
IPO	07/28/2016
Employees	1.086